Effect of endothelin-1 stimulation on peroxisome proliferator-activated receptor-γ expression in vascular smooth muscle cells

Abstract

Abstract: Objective To investigate the effect of endothelin-1 (ET-1) on the expression of peroxisome proliferators-activated receptor-γ in vascular smooth muscle cells. Methods The first to the third passages of aortic vascular smooth muscle cells (VSMCs) isolated from 16-week-old Wistar rats were cultured in vitro and stimulated by ET-1 for 12, 24, 48, and 72 h, respectively, and at different concentrations of ET-1 for 48 h. PPAR-γ mRNA expression of the cells was detected by reverse transcription (RT)-PCR and PPAR-γ protein by Western blotting after the stimulations, and the proliferation of VSMCs was evaluated by MTT assay. Results No changes in PPAR-γ mRNA and protein expressions were observed in the VSMCs after ET-1 stimulation for 12 h (P>0.05), and when the stimulation was prolonged to 24 h, slight decrease in the expressions occurred but the difference was not statistically significant in comparison with the control group (P<0.05). After 48 to 72 hour’s ET-1 stimulation, the expressions of both PPAR-γ mRNA and protein were markedly decreased as compares with the control group (P<0.01). The expressions of PPAR-γ in mRNA and protein were both decreased with the increase of ET-1 concentration after stimulation for 48 h. VSMC proliferation occurred at 12 h during ET-1 stimulation and increased with time and ET-1 concentration. Conclusion ET-1 stimulation can induce VSMC proliferation and decrease the expressions of both PPAR-γ mRNA and protein.

CLC Number:

R543

DI Zheng-li¹, NIU Xiao-lin¹, WEI-Jin¹, GAO Deng-feng¹, WANG Nan-ping². Effect of endothelin-1 stimulation on peroxisome proliferator-activated receptor-γ expression in vascular smooth muscle cells[J]. Journal of Southern Medical University, 2005, 25(09): 1140-1144.

References

[1] Haynes WG, Ferro C J, O’Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans[J]. Circulation, 1996, 93 (10):1860-70.
[2] Ihling C, Bohrmann B, Schaefer HE, et al. Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis-novel targets for pharmacotherapy in atherosclerosis [J]. Curr Vasc Pharmacol, 2004,2(3):249-58.
[3] Kelly DP. The pleiotropic nature of the vascular PPAR gene regulatory pathway[J]. Circ Res, 2001, 89( 11 ):935-7.
[4] Verreth W, De Keyzer D, Pelat M, et al. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice [J]. Circulation, 2004, 110(20):3259-69.
[5] Marx N, DuezH, FruchartJC, et al. Peroxisome proliferatoractivated receptors and atherogenesis:regulators of gene expression in vascular cells[J]. Circ Res, 2004, 94(9):1168-78
[6] Castrillo A, Tontonoz P. PPARs in atherosclerosis:the clot thickens [J].J Clin Invest, 2004, 114(11):1538-40.
[7] Iglarz M, Touyz RM, Amiri F, et al. Effect ofperoxisome proliferatoractivated receptor-alpha and-gamma activators on vascular remodeling in endothelin-dependent hypertension [J]. Arterioscler Thromb Vasc Biol, 2003, 23(1):45-51.
[8] Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis:new perspectives and therapeutic strategies [J].Nat Med, 2002, 8(11):1249-56.
[9] Merkus D, Duncker DJ, Chilian WM. Metabolic regulation of coronary vascular tone:role ofendothelin-1 [J]. Am J Physiol Heart Cire Physiol, 2002, 283(5):1915-192.
[10] Olte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma [J]. Nature, 1998, 395(6698):137-43.
[11] Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling [J]. Am J Physiol Heart Circ Physiol, 2005,288(3):H1037-43.
[12] Hasdai D, Holmes DR Jr, Garratt KN, et al. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo[J]. Circulation, 1997, 95(2):357-62.
[13] Shichiri M, Yokokura M, Marumo F, et al. Endothelin-linhibits apoptosis of vascular smooth muscle cells induced by nitric oxide and serum deprivation via MAP kinase pathway [J]. Arterioscler Thromb Vasc, 2000, 20(4):989-97.
[14] Hinterhuber L, Graziadei IW, Kahler CM, et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension [J]. Clin Gastroenterol Hepatol, 2004, 2(11):1039-42.
[15] Berger J, Moller DE. The mechanisms of action of PPARs [J].Annu Rev Med, 2002, 339:953-95.
[16] Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferatoractivated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway [J]. Circ Res, 1999, 85(5):394-402.
[17] WakinoS, KintscherU, Kim S, et al. Peroxisome proliferatoractivated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 S transition in vascular smooth muscle cells [J].J Biol Chem, 275(29):435-41.
[18] Kintscher U, Lyon C J, Law RE. Angiotensin Ⅱ, PPAR-gamma and atherosclerosis[J]. Front Biosci, 2004, 9:359-69.
[19] Mauricio J. Reginato, Samuel L, et al. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor[J].J Biol, 273(4), 1855-8.
[20] Liu JJ, Huang RW, Lin DJ, et al. Angiotensin Ⅱ and endothelin-1regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells [J].J Hypertens, 2004, 22(6):1141-9.